The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
32
Covance Clinical Research Unit
Daytona Beach, Florida, United States
Covance Dallas
Dallas, Texas, United States
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam
PK: AUC\[0-∞\] of Midazolam
Time frame: Predose up to 24 hours postdose
PK: Maximum Observed Concentration (Cmax) of Midazolam
PK: Cmax of Midazolam
Time frame: Predose up to 24 hours postdose
PK: AUC[0-∞] of Warfarin
PK: AUC\[0-∞\] of Warfarin
Time frame: Predose up to 96 hours postdose
PK: Cmax of Warfarin
PK: Cmax of Warfarin
Time frame: Predose up to 96 hours postdose
PK: AUC[0-∞] of Caffeine
PK: AUC\[0-∞\] of Caffeine
Time frame: Predose up to 48 hours postdose
PK: Cmax of Caffeine
PK: Cmax of Caffeine
Time frame: Predose up to 48 hours postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Administered orally.